Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yang, Yunpeng; Pan, Jianji; Wang, Hui; Zhao, Yuanyuan; Qu, Shenhong; Chen, Nianyong; Chen, Xiaozhong; Sun, Yan; He, Xiaohui; Hu, Chaosu; Lin, Lizhu; Yu, Qitao; Wang, Siyang; Wang, Guihua; Lei, Feng; Wen, Jiyu; Yang, Kunyu; Lin, Zhixiong; Guo, Ye; Chen, Shaoqing; Huang, Xiaoming; Wu, Yanjie; Liang, Liang; Chen, Chenqi; Bai, Fan; Ma, Xiaopeng; Zhang, Yun; Leaw, Shiangjiin; Zhang, Li; Fang, Wenfeng

doi:10.1016/j.ccell.2023.04.014

Public

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Published in Cancer Cell • May 18, 2023

Authors:

Yunpeng Yang

Jianji Pan

Hui Wang

Abstract

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survi...

Subject

Nasopharyngeal cancer

Chemotherapy

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!